Satellos Bioscience Inc. (MSCL) Completes Phase 2 DMD Trial Enrollment; Topline Data Slips to Q1 2027
Satellos completed enrollment in BASECAMP, its Phase 2 trial of forazapadin in ambulatory boys with DMD, and now expects to share topline data in Q1 2027 after adjusting the prior plan to compile a more complete dataset.Material DetailsContext by AI AnalystThis is a mid-stage R&D milestone that con…